Status:
RECRUITING
Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting
Lead Sponsor:
Peking University Third Hospital
Conditions:
Coronary Artery Bypass
Eligibility:
All Genders
25-85 years
Brief Summary
Data from the Global Burden of Disease Study 2021, recently published in the Lancet, show that ischaemic heart disease remains the first most common cause of death worldwide. Ischemic heart disease ma...
Detailed Description
Data from the Global Burden of Disease Study 2021, recently published in the Lancet, show that ischaemic heart disease remains the first most common cause of death worldwide. Ischemic heart disease ma...
Eligibility Criteria
Inclusion
- Patients who received coronary artery bypass surgery with syndrome differentiation of Qi-Yin deficiency after operation
Exclusion
- ① Patients allergic to Fuzheng Yangxin Fang granules
- Patients with postoperative cold and fever ③ Patients with severe postoperative hepatic and renal insufficiency ④ Other circumstances: Concurrent valvular surgery or other cardiac surgery, end-stage malignant tumor, uncontrolled infection, bleeding, progressive degenerative systemic disease, severe brain injury, multiple organ failure, other vital organ dysfunction such as severe liver impairment, severe heart failure or cardiogenic shock, inability to tolerate surgery, etc.
Key Trial Info
Start Date :
May 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06961136
Start Date
May 1 2024
End Date
June 30 2026
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking university third hospital
Beijing, Beijing Municipality, China, 100191